蒲地蓝消炎口服液联合妥布霉素滴眼液治疗细菌性角膜炎的临床疗效  

Clinical Efficacy of Pudilan Anti-inflammatory Oral Liquid Combined with Tobramycin Eye Drops in the Treatment of Bacterial Keratitis

作　　者：杨凡 王冠 方莹 YANG Fan;WANG Guan;FANG Ying(Department of Ophthalmology,Zhengzhou Second People's Hospital,Zhengzhou Henan 450006)

机构地区：[1]郑州市第二人民医院眼科,河南郑州450006

出　　处：《医学临床研究》2024年第1期43-46,共4页Journal of Clinical Research

摘　　要：【目的】探讨蒲地蓝消炎口服液联合妥布霉素滴眼液治疗细菌性角膜炎的临床疗效。【方法】选择2020年4月至2023年4月本院收治的82例细菌性角膜炎患者,按照随机数字表法分为观察组和对照组,每组41例。对照组采用妥布霉素滴眼液治疗,观察组在对照组的基础上加用蒲地蓝消炎口服液治疗,两组均治疗14 d。比较两组临床疗效、不良反应发生率及治疗前后临床症状评分、γ-干扰素(IFN-γ)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、免疫功能指标水平。【结果】治疗后,两组疼痛症状评分、分泌物症状评分、溃疡面积症状评分、结膜充血症状评分均降低(P<0.05),且观察组更低(P<0.05)。观察组总有效率为92.68%,显著高于对照组的75.61%,差异有统计学意义(P<0.05)。与治疗前比较,两组治疗后血清IFN-γ水平均升高(P<0.05),且观察组更高(P<0.05);两组治疗后血清IL-6、TNF-α水平均降低(P<0.05),且观察组更低(P<0.05)。与治疗前比较,两组治疗后CD3^(+)、CD4^(+)水平均升高(P<0.05),且观察组更高(P<0.05);两组治疗后CD8^(+)水平均降低(P<0.05),且观察组更低(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】蒲地蓝消炎口服液联合妥布霉素滴眼液治疗细菌性角膜炎,效果确切,可改善患者临床症状及免疫功能,减轻炎症反应,且安全可靠。【Objective】To explore the clinical efficacy of Pudilan anti-inflammatory oral liquid combined with Tobramycin eye drops in the treatment of bacterial keratitis.【Methods】A total of 82 patients with bacterial keratitis admitted to our hospital from April 2020 to April 2023 were randomly divided into an observation group and a control group,with 41 cases in each group,using a random number table method.The control group was treated with tobramycin eye drops,while the observation group was treated with Pudilan anti-inflammatory oral solution in addition to the control group.Both groups were treated for 14 days.We compared the clinical efficacy,incidence of adverse reactions,clinical symptom scores before and after treatment,levels of interferonγ(IFN-γ),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),and immune function indicators between two groups.【Results】After treatment,the pain symptom score,secretion symptom score,ulcer area symptom score,and conjunctival congestion symptom score of both groups decreased(P<0.05),and the observation group had a lower score(P<0.05).The total effective rate of the observation group was 92.68%,significantly higher than the control group's 75.61%,and the difference was statistically significant(P<0.05).Compared with before treatment,the serum IFN-γlevels in both groups increased after treatment(P<0.05),and the observation group had a higher level(P<0.05);After treatment,the serum levels of IL-6 and TNF-αdecreased in both groups(P<0.05),and the observation group had lower levels(P<0.05).Compared with before treatment,the levels of CD3^(+)and CD4^(+)in both groups increased after treatment(P<0.05),and the observation group had a higher level(P<0.05);After treatment,the levels of CD8^(+)decreased in both groups(P<0.05),and the observation group had a lower level(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).【Conclusion】The combination of Pudilan anti-inflammatory oral liquid a

关 键 词：角膜炎/药物疗法 妥布拉霉素/治疗应用 蒲地蓝消炎口服液/治疗应用 治疗结果 

分 类 号：R772.22[医药卫生—眼科]